Chemical structures have been identified which allosterically modify pyrvate kinase and inhibit enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying hemoglobin's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease (AD).
[EN] ALLOSTERIC INHIBITORS AND ACTIVATORS OF PYRUVATE KINASE<br/>[FR] INHIBITEURS ALLOSTERIQUES ET ACTIVATEURS DE PYRUVATE KINASE
申请人:ALLOS THERAPEUTICS, INC.
公开号:WO1999048490A1
公开(公告)日:1999-09-30
(EN) Chemical structures have been identified which allosterically modify pyruvate kinase and either inhibit or activate enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate.(FR) L'invention concerne des structures chimiques modifiant de manière allostérique une pyruvate kinase et inhibant ou activant une activité enzymatique. Ces composés peuvent s'utiliser comme produits pharmaceutiques pour le traitement d'une grande variété d'affections et de troubles pour lesquels il est bénéfique d'influencer les réactions métaboliques, comme la voie glycolytique, toutes les voies utilisant ATP comme source d'énergie et toutes les voies comprenant 2,3-diphosphoglycérate.